Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-02

Clinical Trial Update: A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluated single-dose gabapentin for transient insomnia; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gabapentin (Gabapentin)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Transient Insomnia | Phase 3 | Status: COMPLETED